Documento fuente o registro público

FDA 510(k) K221640 — AlloMap Heart Molecular Expression Testing

FDA 510(k) index record K221640. Device: AlloMap Heart Molecular Expression Testing. Applicant as listed: Caredx, Inc.. Decision date: 2023-09-13.

OtherU.S. Food and Drug Administration (FDA)2023-09-13

Fuente

"device_name": "AlloMap Heart Molecular Expression Testing"

Esta entrada describe lo que cubre el documento; el propio documento es la autoridad. Incluirlo no implica estar de acuerdo con sus conclusiones.

Review and references

Reviewer

Automated FDA record verification

Published

2026-10-20

Updated

2026-10-28

Disclaimer

professional use

FDA 510(k) public index record K221640.

Device name: AlloMap Heart Molecular Expression Testing. Applicant as listed: Caredx, Inc..

Decision date: 2023-09-13. Decision wording: Substantially Equivalent.

Product code: OJQ. Regulation: 21 CFR 862.1163. Medical specialty: Cardiovascular.

This page reproduces regulator index metadata. The applicant field identifies the submitter and is not a manufacturer identity check. Consult the original FDA record for the decision and associated documents; this index does not verify current commercial availability or clinical performance.

Interested in these solutions?

Submit a sourcing request with the assays, volumes, and timeline of your own project.

Explorar más